James Gallagher

James Gallagher is a health and science correspondent at the BBC whose work follows cutting-edge medicine from the laboratory to the clinic, anchored in what it means for patients and public health. He presents the Radio 4 programme Inside Health and major documentary series that turn complex evidence on noise, microbes and the brain into clear, accessible stories. His recent reporting runs from rare-disease breakthroughs and organ transplants to everyday decisions about weight, new drugs and digital health advice.

Rare diseases, transplants and ‘game‑changing’ treatments

Gallagher repeatedly focuses on pioneering interventions for people with conditions that have long been considered incurable or unmanageable. He has covered a rare-diseases study that saved a girl’s life, explaining how advanced genetic analysis and bespoke treatment plans can transform individual outcomes. In analysis of a man whose £2.6m worth of clotting-factor therapy has “cured” his haemophilia, he sets out both the science of the treatment and what long-term disease control means for daily life.

His reporting on a pig kidney that functioned in a human body for 271 days asks whether xenotransplantation could ease organ shortages, balancing surgical detail with questions about risk, ethics and future adoption.

He follows experimental technologies as they move into the clinic, including an implant that restores hand and arm control years after stroke and a test that prevents babies from going deaf by screening for genetic susceptibility to certain antibiotics. Coverage of brain surgery that uses live adult tissue to study dementia and other diseases shows him inside the operating theatre, using the procedure to explain how scientists hunt for clues to conditions such as Alzheimer’s and to assess new drugs like lecanemab and donanemab.

Across these pieces, and in work on immune “reset” treatments that push severe autoimmune diseases such as lupus into remission, he treats each case as a way to examine how fast, and how safely, medicine is changing.

His longer-form projects extend this focus, with documentary series such as The Inflamed Mind and The Second Genome investigating the role of the immune system in mental health and the microbes that live in and on the body. That body of work gives him a consistent vantage point on how basic biology and emerging therapies reshape definitions of disease, cure and risk.

Superbugs, outbreaks and global health threats

Gallagher’s beat includes tracking infectious threats and drug resistance, with a particular emphasis on how global trends translate into local risk. He has reported on more transmissible forms of mpox, pairing news of the first such case detected in the UK with practical guidance on what changing viral behaviour means for communities. Pieces on malaria highlight both a major vaccine advance against a leading child killer and the growing problem of parasites resisting key antimalarial drugs, framing individual scientific milestones within the wider struggle against infection.

He covers the rise of superbugs through stories on the Longitude Prize for diagnostic innovation and on fake Ozempic circulating worldwide, linking antibiotic resistance, poor regulation and the demand for quick fixes. Reporting on ticks and other tiny bloodsuckers, he joins field hunts to show how changing ecosystems are driving new patterns of disease. In features asking whether a fungal pandemic could “turn us all into zombies” and whether laboratories can help stop the next pandemic, he uses vivid hooks to draw readers into serious examinations of preparedness, surveillance and scientific responsibility.

His broadcast work carries this thread into global experiments in disease control, including explaining a project backed by Google to release millions of mosquitoes in the United States to curb infections such as dengue. Taken together, these stories build a picture of a reporter who treats every outbreak or resistance warning as part of a larger narrative about how societies manage risk and adapt to evolving microbes.

Weight, drugs and the everyday body

Alongside frontier science, Gallagher spends considerable time on the everyday pressures people face around weight, diet and appearance.

He has analysed NHS-backed strategies that focus on “lose a little, keep it off” weight-loss plans and questioned whether appetite-suppressing injections are really the answer to obesity, pulling together evidence on effectiveness, side effects and long-term outcomes. His coverage of why “everyone is talking about Ozempic and Wegovy” and of a global alert over fake versions of these drugs shows him following the social and commercial momentum around weight-loss medications while stressing the dangers of counterfeit supplies.

He examines how early-life exposures shape health, as in reporting that high sugar intake during the first 1,000 days is linked to poorer outcomes later, and he covers advances such as DIY cervical-cancer testing kits that could add millions more screening opportunities. Work on inflammatory bowel disease and other chronic conditions similarly combines explanation of underlying mechanisms with practical implications for patients. In an Inside Health investigation into men seeking penis fillers despite the risks, he visits clinics, interviews patients and surgeons, and sets out the weak evidence base and significant complication rates, framing the story as part of a wider trend in body modification and medicalised self-image.

Across these pieces he treats the body as both biological system and social object, showing how clinical data, marketing and personal anxiety intersect in decisions about food, exercise, drugs and cosmetic procedures.

Noise, AI and explaining complex science across platforms

Gallagher’s work also explores less obvious health hazards and new technologies that promise to reshape care. In the multi-part documentary LOUD: Is noise an invisible killer? he spends more than a year investigating how chronic exposure to sound - from busy cities like Barcelona and Dhaka to everyday urban environments - raises risks of heart disease, sleep problems, anxiety and shortened life expectancy. He participates in laboratory experiments in London to show how noise alters the body’s stress responses, turning an abstract concept into something measurable and immediate.

He brings the same approach to digital health, reporting on whether “AI doctors” and chatbots can be trusted for medical advice.

That coverage sets out specific concerns raised by senior health officials and new studies showing that more than half of AI-generated answers on topics such as cancer, vaccines and nutrition contain problematic information, underlining how confident language can mask inaccurate guidance. In pieces on artificial intelligence being used to design brand-new viruses and on efforts to build an atlas of the body’s 37 trillion cells, he explains how computational tools and large-scale mapping projects are transforming biology.

Gallagher regularly translates complex scientific work on microRNAs, “genetic ghosts” that help trace Covid’s origins, and other molecular topics into plain prose, whether through news analysis or longer essays. He broadcasts across the BBC’s television, radio and online platforms, and his work is carried in multiple language services, extending the reach of his health and science reporting far beyond any single audience. The through-line is a reporter who is as comfortable inside a lab or operating theatre as he is testing technology on himself or walking noisy streets, always with the aim of showing how abstract science connects to real lives.